Onset of alcohol or substance use disorders following treatment for adolescent depression
Autor: | Jerry Kirchner, Paul Rohde, Anne D. Simons, Karen C. Wells, John F. Curry, John T. Walkup, Norah Feeny, Beth Kennard, Elizabeth B. Weller, Mark A. Reinecke, Barbara J. Burns, Sarah Lavanier, Elizabeth Kastelic, Taryn L. Mayes, Golda S. Ginsburg, Emily Becker-Weidman, John S. March, Susan G. Silva, Rachel H. Jacobs, Graham J. Emslie, Christopher J. Kratochvil, Diane May, Anne Marie Albano |
---|---|
Rok vydání: | 2012 |
Předmět: |
Male
medicine.medical_specialty Adolescent Substance-Related Disorders medicine.medical_treatment Alcohol abuse Placebo behavioral disciplines and activities Article law.invention Randomized controlled trial law Fluoxetine mental disorders medicine Humans Psychiatry Depression (differential diagnoses) Depressive Disorder Major Cognitive Behavioral Therapy medicine.disease Combined Modality Therapy Antidepressive Agents Substance abuse Cognitive behavioral therapy Psychiatry and Mental health Clinical Psychology Treatment Outcome Major depressive disorder Female Psychology Follow-Up Studies medicine.drug |
Zdroj: | Journal of Consulting and Clinical Psychology. 80:299-312 |
ISSN: | 1939-2117 0022-006X |
DOI: | 10.1037/a0026929 |
Popis: | Objective This study tested whether positive response to short-term treatment for adolescent major depressive disorder (MDD) would have the secondary benefit of preventing subsequent alcohol use disorders (AUD) or substance use disorders (SUD). Method For 5 years, we followed 192 adolescents (56.2% female; 20.8% minority) who had participated in the Treatment for Adolescents with Depression Study (TADS; TADS Team, 2004) and who had no prior diagnoses of AUD or SUD. TADS initial treatments were cognitive behavior therapy (CBT), fluoxetine alone (FLX), the combination of CBT and FLX (COMB), or clinical management with pill placebo (PBO). We used both the original TADS treatment response rating and a more restrictive symptom count rating. During follow-up, diagnostic interviews were completed at 6- or 12-month intervals to assess onset of AUD or SUD as well as MDD recovery and recurrence. Results Achieving a positive response to MDD treatment was unrelated to subsequent AUD but predicted a lower rate of subsequent SUD, regardless of the measure of positive response (11.65% vs. 24.72%, or 10.0% vs. 24.5%, respectively). Type of initial MDD treatment was not related to either outcome. Prior to depression treatment, greater involvement with alcohol or drugs predicted later AUD or SUD, as did older age (for AUD) and more comorbid disorders (for SUD). Among those with recurrent MDD and AUD, AUD preceded MDD recurrence in 24 of 25 cases. Conclusion Effective short-term adolescent depression treatment significantly reduces the rate of subsequent SUD but not AUD. Alcohol or drug use should be assessed prior to adolescent MDD treatment and monitored even after MDD recovery. |
Databáze: | OpenAIRE |
Externí odkaz: |